Insulin-induced normoglycemia has shown to have a beneficial effect on the outcome of pancreatic islets transplanted to diabetic recipients. The aim of the study was to identify the insulin treatment that can maxi mize its beneficial effect on islet transplants. Six groups of streptozotocin diabetic C57B1/6 mice were transplanted (Tx) with 100 syngeneic islets, an insufficient beta cell mass to restore normoglycemia, and were treated with insulin as follows: group 1 (n = 9): from day 10 before Tx to day 14 after Tx; group 2 (n = 11): from day 6 before Tx to Tx day ; group 3 (n = 11): from Tx day to day 6 after Tx; group 4 (n = 7): from Tx day to day 14 after Tx; group 5 (n = 8): from day 10 to day 24 after Tx; group 6 (n = 18): Tx mice were not treated with insulin. Sixty days after Tx, normoglycemia was achieved in 100% of mice in groups 1, 4, and 5, in 73% of mice in group 2, and in only 45% and 33% of mice in groups 3 and 6, respectively (p < 0.01). Intraperitoneal glucose tolerance, determined only in normoglycemic mice, was similar in groups 1, 2, 4, and normal controls. In contrast, normoglycemic mice from groups 3, 5, and 6, exposed to more severe and prolonged hyperglycemia after Tx, showed higher glucose values after glucose injection, suggest ing that hyperglycemia had a long-lasting deleterious effect on transplanted beta cell function. The initially transplanted beta cell mass was maintained in the grafts of normoglycemic mice, but was severely reduced in hyperglycemic mice. Transplanted beta cell mass was similar in normoglycemic groups with normal or impaired glucose tolerance, indicating that impaired glucose tolerance was not due to reduced beta cell mass. In summary, the beneficial effect of insulin-induced normoglycemia on transplanted islets was maximal when insulin treatment was maintained the initial 14 days after transplantation. Exposure to sustained hyper glycemia initially after transplantation had a long-lasting deleterious effect on transplanted islets.
INTRODUCTION
Chronically elevated glucose levels can cause beta cell dysfunction (18, 30, 36) , and transplanted islets ex posed to sustained hyperglycemia have shown impaired beta cell function (8, 10, 15, 35) , limited replicative capac ity, and reduced beta cell mass (23, 24, 26) . In addition, hyperglycemia reduced blood perfusion and delayed re vascularization of the graft in several, but not all, studies (11, 21, 33) .
In the initial days after transplantation hyperglycemia has been related to increased beta cell death (4) and re duced beta cell mass (4, 24) . However, islets exposed to mild hyperglycemia several weeks after transplantation showed increased beta cell replication and mass (12, 25, 27) , suggesting that transitory hyperglycemia could have a posi tive effect on transplanted islets. Thus, the effects of hyper glycemia on transplanted islets could depend on the sever ity, duration, and timing of exposure to hyperglycemia.
Insulin treatment has shown a beneficial effect on transplanted islets (14, 23, 28) . We recently reported that normoglycemic, insulin-treated diabetic mice achieved permanent normoglycemia with the transplantation of an otherwise insufficient beta cell mass (23) ; in contrast, non-insulin-treated mice remained hyperglycemic. How ever, a few hyperglycemic, non-insulin-treated mice eventually achieved normoglycemia after transplanta tion. Interestingly, these animals showed an abnormal glucose tolerance compared to mice that were normogly cemic when transplanted, suggesting that beta cell func tion was impaired by the previous exposure to hypergly cemia. Therefore, the aim of this study was to identify the insulin administration regime that could maximize the beneficial effect of insulin on transplanted islets. In addition, we sought to determine whether transitory ex posure of transplanted islets to hyperglycemia immedi ately after transplantation could have a long-lasting dele terious effect on transplanted beta cells.
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MATERIALS AND METHODS
Male inbred C57B1/6 mice (B&K Universal, Humberside, UK) aged 7-10 weeks, were used as donors and recipients of transplantation. The recipients were made diabetic by a single IP injection of streptozotocin (Sigma Immunochemicals, St. Louis, MO) 180 mg/kg b.wt., freshly dissolved in citrate buffer (pH 4.5). Before trans plantation, diabetes was confirmed by the presence of hyperglycemia, weight loss, and polyuria. Only those mice with a blood glucose higher that 20 mmol/l were transplanted. Blood glucose was determined between 0900 and 1100 h in nonfasting conditions. Blood was obtained from the snipped tail with a heparinized microcapillary tube and glucose was measured with a portable glucose meter (Reflolux II, Boehringer Mannheim Biochemicals, Mannheim, Germany). Animals were kept under conventional conditions in climatized rooms with free access to tap water and standard pelleted food.
Experimental
Groups and Insulin Treatment
Six groups of STZ-diabetic mice were studied. Five to 14 days after STZ injection, diabetic mice were ran domly distributed among groups and treated as summa rized in Figure 1 . All six groups received a 100 synge neic islet transplantation under the left kidney capsule on day 0. This is an insufficient beta cell mass to consis tently restore normoglycemia and most mice were ex pected to remain hyperglycemic after transplantation. In addition, groups 1 to 5 were treated with sustained re lease insulin implants (LinBits, Linshin Canada, Inc., Scarborough, Canada) as previously described (23) .
Groups were treated as follows: group 1 (n = 9): from day 10 before transplantation to day 14 after transplanta tion; group 2 (n = 11): from day 6 before transplantation to transplantation day; group 3 (n = 11): from transplan tation day to day 6 after transplantation; group 4 (n = 7):
from transplantation day to day 14 after transplantation; group 5 (n = 8): from day 10 to day 24 after transplanta tion. Group 6 (n = 18) was not treated with insulin. All grafts were harvested 60 days after transplantation. A control group (n = 6) of normal nontransplanted mice had their blood glucose and body weight determined weekly.
The rational for insulin treatment in group 1 was to maintain normoglycemia (blood glucose < 9.0 mmol/l; mean ± 2 SD of blood glucose in control group) from at least day 6 before transplantation to the completion of vascularization on day 14 after transplantation. In groups 2 and 3, insulin treatment was given to assess the effects of short-term normoglycemia immediately before 
Islet Isolation, Transplantation, and Graft Harvesting
Islets were isolated by collagenase (collagenase P, Boehringer Mannheim Biochemicals) digestion of the pancreas as previously described (23) . Isolated islets were handpicked under a stereomicroscope two or three times until a population of pure islets was obtained.
Only those islets >75 and <250 pm in diameter were collected and counted into groups of 100 islets, which were transplanted under the left kidney capsule of the recipient on the day of the isolation. After transplanta tion, the capsulotomy was cauterized with a disposable low-temperature cautery pen (F.L. Fischer Bipolator, Berlin, Germany) and the lumbar incision was sutured.
To harvest the graft, the kidney was exposed with the mouse under light ether anesthesia. The graft was identi fied as a white patch in normoglycemic mice, and a more translucent graft was found in hyperglycemic mice. The kidney capsule surrounding the graft was in cised and removed with the graft.
Intraperitoneal Glucose Tolerance Test (IPGTT)
IPGTT was performed on days 54-58 after transplan tation in all normoglycemic animals and in control mice of similar age. Between 
Beta Cell Mass
Methods used for measurement of beta cell mass have been described in detail (24) . Beta cell mass was measured by point counting morphometry on immunoperoxidase-stained sections of grafts with an Olympus BH2 microscope connected to a video camera with a color monitor. A 48-point grid was used to obtain the number of intercepts over beta cells, over endocrine non-beta cells, and over other tissue. The beta cell mass of islets at the time of transplantation was determined in eight groups of 100 islets isolated on different days.
Statistical Analysis
Results were expressed as mean ± SEM. 
RESULTS
Metabolic Evolution
The characteristics of experimental groups are sum marized in 4 and 5, and in six (33%) mice of group 6 (p<0.01 between groups 3 and 6 and all other groups) (Fig. 2) . In groups 2 and 4, transitory hyperglycemia after trans plantation was mild (<14 mmol/l), and definitive nor moglycemia was achieved 12.6 + 2.9 and 22.6 ±3.7 days, respectively, after transplantation. In contrast, groups 3, 5, and 6 experienced severe hyperglycemia (>20 mmol/l) 10 or more days after transplantation, and definitive normoglycemia was not achieved until day 33.4 ± 5.3 in group 3, day 30.6 + 2.4 in group 5, and day 35.1 ± 4.0 in group 6. Mice that eventually achieved normoglycemia and those that remained hyperglycemic showed similar characteristics when they were injected with streptozotocin, started on insulin, or transplanted.
In all normoglycemic mice recurrence of hyperglyce mia was confirmed on days 2 and 7 after graft harvest s' ing. In two mice blood glucose did not achieve 20 mmol/l, and they were excluded from the study. Severe hyperglycemia (>20 mmol/l) and weight loss persisted in all mice on day 7 after graft harvesting, and were similar in all groups (Table 1) .
Six hyperglycemic mice (one in group 2, two in group 3, and three in group 6) were severely ill after the withdrawal of insulin treatment and required additional transitory (less that 7 days) insulin administration; all these mice were hyperglycemic at the end of the study.
IPGTT
IPGTT test was performed only in normoglycemic mice. After IP glucose injection, glucose levels at spe cific time points and glucose AUC were similar in con trol group and normoglycemic mice of groups 1, 2, and 4 ( Fig. 3) . Group 5 had higher glucose values after 120 min (group 5: 13.7 ± 1.0 mmol/l; control group: 9.3 ± 0.5 mmol/l; p = 0.002) and group 6 showed a higher glu cose peak (group 6: 22.4 ± 1.8 mmol/l; control group: 16.0 ±0.6 mmol/l; p = 0.006). The AUC was higher in groups 3 (3584 ±179 mM/min), 5 (3629 ±177 mM/ min), and 6 (3916 + 324 mM/min) compared to the con trol group (2890 ± 125 mM/min, p < 0.008) (Fig. 3) .
Beta Cell Mass
When graft sections from six normoglycemic mice were stained for the endocrine non-beta cells or for the beta cells, beta cell mass was 0.20 ± 0.03 and 0.18 ± 0.04 mg (r = 0.99), respectively, confirming the validity of staining the endocrine non-beta cells to determine beta cell mass. The initially transplanted beta cell mass was maintained in all normoglycemic grafts at the end of follow-up, with no significant differences among groups. In contrast, beta cell mass was severely reduced in hyperglycemic mice (Table 2 ). There was no correla tion between the individual beta cell mass values in the grafts and the glucose levels after IP glucose chal lenge.
DISCUSSION
In this study, we have shown that the beneficial effect of insulin treatment on the outcome of syngeneically transplanted islets was determined by the timing and du ration of insulin-induced normoglycemia in the diabetic recipients of the transplants. The beneficial effect of in sulin was maximal in groups 1 and 4, which maintained normoglycemia throughout the initial 14 days after transplantation; all mice achieved definitive normogly cemia and glucose tolerance was normal despite the transplantation of an otherwise insufficient beta cell mass. In contrast, the shorter 6-day posttransplantation treatment in group 3 did not improve the metabolic evo lution compared to non-insulin-treated mice. A similar 6-day insulin treatment given exclusively before trans plantation afforded some protection, and most mice achieved definitive normoglycemia, indicating that maintaining normoglycemia on transplantation day is beneficial. When insulin treatment was postponed and transplanted islets were initially exposed to hyperglyce mia, the beneficial effect of insulin was reduced and, even if normoglycemia was finally achieved, mice showed impaired glucose tolerance. Beta cell mass was similar in normoglycemic groups with normal and im paired glucose tolerance, indicating that impaired glu cose tolerance was not due to reduced beta cell mass and suggesting that hyperglycemia had a long-lasting detrimental effect on transplanted beta cell function.
After transplantation, a minimum duration of insulininduced normoglycemia was required to improve the outcome of the graft. In group 3, 6 days of insulin after transplantation did not increase the percentage of mice that achieved definitive normoglycemia. In contrast, all mice in groups 1 and 4 achieved definitive normogly cemia after 14 days of insulin. The requirement of a minimum normoglycemic period after transplantation may be related to the effects of hyperglycemia on revas cularization and oxygen requirement of transplanted beta cells. Transplanted islets are devoid of vasculariza tion in the first days after transplantation, they begin to revascularize around day 4 after transplantation, and vascularization is completed after 10-14 days (2, 22) . Although the effects of hyperglycemia on angiogenesis of transplanted islets have been controversial, it has been reported that revascularization of the graft can be de layed by hyperglycemia (11, 33) . In addition, hypergly cemia could increase the hypoxia of transplanted islets because islets exposed to hyperglycemia have a higher oxygen requirement that cannot be met by diffusion in nonvascularized islets (6) , resulting in beta cell death and compromised insulin secretion (7) of surviving is lets. Our data give experimental support to the recent suggestion that prolongation of insulin treatment after transplantation may reduce the presence of early graft failure and extend the survival of the graft in type I dia betic patients (1).
The beneficial effects of maintaining normoglycemia on transplantation day were apparent in group 2, which was treated with insulin exclusively before transplanta tion. Only 27% of mice in this group did not achieve normoglycemia after transplantation. Short-term hyper glycemia has been shown to induce insulin resistance in diabetic animal models (31) and type I diabetic patients (34, 37) , and correction of hyperglycemia improved insu lin sensitivity (17, 32) . Thus, normoglycemic, insulintreated recipients of islet grafts were probably more in sulin sensitive than hyperglycemic mice. In a different model using 95% pancreatectomized rats, we reported that restoring normoglycemia required a higher beta cell mass than maintaining normoglycemia, and suggested that the different insulin sensitivity of normoglycemic and hyperglycemic recipients had played a role in the different beta cell mass requirement (25) . The reduced insulin resistance of normoglycemic group 2 mice on transplantation day may have facilitated the achievement of definitive normoglycemia with the transplantation of a low beta cell mass.
Hyperglycemia had a long-lasting deleterious effect on transplanted beta cell function, even when normogly cemia was eventually achieved. Mice exposed to sus tained and severe hyperglycemia after transplantation showed an abnormal tolerance more than 3 weeks after the restoration of normoglycemia. In contrast, mice per sistently normoglycemic after transplantation or exposed to short-term moderate hyperglycemia showed normal glucose tolerance at the end of follow-up. The detrimen tal effect of chronic exposure to high glucose concentra tions on beta cell function has been shown in cultured rodent (13, 29) and human (5,9) islets, and in animal models (3, 19) . In transplanted islets, the deleterious ef fect of hyperglycemia on beta cell function and the ben eficial effects of normoglycemia have been described in mouse and human islets (8, 10, 15, 35) . Islets syngeneically transplanted to normoglycemic insulin-treated recip ients showed preserved insulin content compared to is lets exposed to hyperglycemia and were able to increase their beta cell mass to meet an increased metabolic de mand (23) . Human islets transplanted to diabetic nude mice showed the recovery of normal insulin content, in sulin biosynthesis, glucose oxidation, and expression of insulin mRNA when normoglycemia was restored after sustained hyperglycemia (8) . However, defective glu cose-induced insulin release was still found after 2 weeks of normoglycemia, suggesting that the insulin se cretion defect induced by hyperglycemia could be of long duration or even permanent (10) . The similar beta cell mass that we found in grafts of mice with impaired glucose tolerance, and previously exposed to sustained and severe hyperglycemia, and mice with normal glu cose tolerance further supports the concept that hyper glycemia may have long-term deleterious effects on beta cell function. In this study, we used a mouse strain that has shown resistance to glucose-induced beta cell dys function (16, 20) . Thus, it is possible that the beneficial effect of insulin-induced normoglycemia could be even higher in human transplanted islets, which have shown a high sensitivity to the deleterious effects of high glucose concentrations (13) .
In summary, both duration and timing of insulin-in duced normoglycemia determined the beneficial effects on transplanted islets: when islets were transplanted to normoglycemic insulin-treated recipients the outcome of the transplants was partially improved, but the beneficial effect of normoglycemia was maximal when insulin treatment was maintained throughout the revasculariza tion period. Exposure to sustained hyperglycemia ini tially after transplantation had a long-term deleterious effect on transplanted beta cells.
